Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.680
+0.030 (1.82%)
At close: Aug 13, 2025, 4:00 PM
1.580
-0.100 (-5.95%)
Pre-market: Aug 14, 2025, 4:38 AM EDT
Cocrystal Pharma Employees
Cocrystal Pharma had 11 employees as of December 31, 2024. The number of employees decreased by 1 or -8.33% compared to the previous year.
Employees
11
Change (1Y)
-1
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$1,440,818
Market Cap
17.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
COCP News
- 9 days ago - Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference - GlobeNewsWire
- 5 weeks ago - Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference - GlobeNewsWire
- 2 months ago - Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference - GlobeNewsWire
- 2 months ago - Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - GlobeNewsWire
- 2 months ago - Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - GlobeNewsWire
- 4 months ago - Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - GlobeNewsWire